نتایج جستجو برای: braf mutation

تعداد نتایج: 295289  

Journal: :Oncology reports 2011
Rosario Rivera Buery Chong Huat Siar Naoki Katase Mehmet Gunduz Mathieu Lefeuvre Masae Fujii Masahisa Inoue Kojun Setsu Hitoshi Nagatsuka

Oral mucosal melanoma (OMM) is a fatal sarcoma of unknown etiology. Histological morphology and genetic events are distinct from those of its cutaneous counterpart. Mutation and up-regulation of c-kit has been identified in OMM which may activate downstream molecules such as RAS and RAF. These molecules are involved in the mitogen-activated protein kinase (MAPK) pathway leading to tremendous ce...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2004
Masaru Shinozaki Akihide Fujimoto Donald L Morton Dave S B Hoon

PURPOSE The purpose of the study was to clarify the incidence of B-raf oncogene (BRAF) mutations in primary cutaneous melanomas, their relation to tumor progression, and effect on disease outcome. Somatic mutations of BRAF kinase, a component of the Ras-mitogen-activated protein/extracellular signal-regulated kinase kinase-mitogen-activated protein kinase pathway, are frequently reported (>65%)...

2014
Sang Jin Kim Hyoung Ran Kim Seok Hyung Kim Ji Hye Han Yong Beom Cho Seong Hyeon Yun Woo Yong Lee Hee Cheol Kim

PURPOSE Sporadic colorectal cancers with high-frequency microsatellite instability (MSI-H) are related to hypermethylation of mismatch repair (MMR) genes and a higher frequency of BRAF mutations than Lynch syndrome. We estimated the feasibility of hereditary colorectal cancer based on hMLH1 methylation and BRAF mutations. METHODS Between May 2005 and June 2011, we enrolled all 33 analyzed pat...

Journal: :Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006
Jana Vandrovcova Kristina Lagerstedt-Robinsson Lars Påhlman Annika Lindblom

The BRAF gene is mutated in 4% to 12% of unselected colorectal cancers, particularly those with high microsatellite instability and in premalignant lesions, such as serrated adenomas and hyperplastic polyps. However, it has been shown that activating BRAF mutations are almost never found in tumors from hereditary nonpolyposis colorectal cancer patients. To evaluate the role of oncogenic BRAF mu...

Journal: :American journal of clinical pathology 2012
Kurt D Bernacki Bryan L Betz Helmut C Weigelin Christopher D Lao Bruce G Redman Stewart M Knoepp Michael H Roh

Patients with advanced-stage melanoma harboring a BRAF mutation are candidates for BRAF inhibition as a therapeutic strategy. The use of fine-needle aspiration (FNA) to diagnose metastatic melanoma is increasing. Studies examining the predictive value of BRAF mutation analysis on melanoma FNAs via correlation with follow-up excision findings are lacking. We examined 37 consecutive FNA cases of ...

Journal: :Molecular cancer therapeutics 2008
Udai Banerji Annette Affolter Ian Judson Richard Marais Paul Workman

Oncogenic BRAF and NRAS mutations are frequent in malignant melanoma. BRAF that is activated by the common V600E and other mutations, as well as by upstream NRAS mutations, has been shown to require the molecular chaperone heat shock protein 90 (HSP90) for stabilization and is depleted by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG)]. Here, we explore the possible relatio...

2016
Yoon Yang Jung Woo Hee Jung Ja Seung Koo

The aim of this study is to investigate the BRAF mutation status using BRAF V600E mutation specific antibody in human breast cancer tissue, and discuss its clinical implications. Immunohistochemical staining for BRAF V600E mutation specific antibody was performed using tissue microarrays of 230 cases of breast cancer and 132 cases of triple-negative breast cancer (TNBC). The cases were subdivid...

Journal: :Journal of the Chinese Medical Association : JCMA 2010
Kam-Tsun Tang Chen-Hsen Lee

Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85-90% of all thyroid cancers. Genetic alternations involving the mitogen-activated protein kinase (MAPK) pathway are frequently demonstrated in PTC, such as RET/PTC, RAS, and B-type Raf kinase (BRAF) mutations. Over 90% of BRAF mutations are T1799A, resulting in a BRAF(V600E) mutation. BRAF(V600E) is present...

Journal: :JAMA 2013
Mingzhao Xing Ali S Alzahrani Kathryn A Carson David Viola Rossella Elisei Bela Bendlova Linwah Yip Caterina Mian Federica Vianello R Michael Tuttle Eyal Robenshtok James A Fagin Efisio Puxeddu Laura Fugazzola Agnieszka Czarniecka Barbara Jarzab Christine J O'Neill Mark S Sywak Alfred K Lam Garcilaso Riesco-Eizaguirre Pilar Santisteban Hirotaka Nakayama Ralph P Tufano Sara I Pai Martha A Zeiger William H Westra Douglas P Clark Roderick Clifton-Bligh David Sidransky Paul W Ladenson Vlasta Sykorova

IMPORTANCE BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role in PTC-related patient mortality has not been established. OBJECTIVE To investigate the relationship between BRAF V600E mutation and PTC-related mortality. DESIGN, SETTING, AND PARTICIPANTS Retrospective study of 1849 patients (1411 women and 438 men) with a median age of 46 years (interquartile ra...

Journal: :Molecular cancer therapeutics 2014
Yusuke Narita Kiyoshi Okamoto Megumi Ikemori Kawada Kazuma Takase Yukinori Minoshima Kotaro Kodama Masao Iwata Norimasa Miyamoto Kohei Sawada

Many clinical cases of acquired resistance to the BRAF inhibitor vemurafenib have recently been reported. One of the causes of this acquired resistance is the BRAF downstream kinase point mutation MEK1-C121S. This mutation confers resistance to not only vemurafenib, but also to the allosteric MEK inhibitor selumetinib (AZD6244). Here, we investigated the pharmacologic activities and effectivene...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید